Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040155 · ClinicalTrials.gov registry record · NA
Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT02040155: Completed NA study, sponsored by Duke University.
NCT02040155 is a NA study that has completed, run by Duke University. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02040155, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an observational study. The purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment. Women with gynecologic cancers treated with brachytherapy as part of their standard therapeutic regimen will represent the study population.
Primary Outcome
This will only be possible in a subset of women whose implant geometry will result in a radially symmetric dose cloud (i.e. vaginal cylinder cases) so that both the nanoFOD and the reference dosimeter may be placed in a position expected to have the same, or closely similar dose.
Interventions
- DEVICE Novel nano-scintillator fiber-optic dosimeter (nanoFOD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-08 |
| Phase | NA |
What the finished NCT02040155 record still lists
NCT02040155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Novel nano-scintillator fiber-optic dosimeter (nanoFOD) is the first listed.
NCT02040155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02040155 about?
NCT02040155 is a clinical study titled "Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy". This is an observational study. The purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment. Women with gynecologic cancers treated with brachytherapy as part of their standard thera...
What is the current status of trial NCT02040155?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2014-02. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02040155?
The interventions under investigation include: Novel nano-scintillator fiber-optic dosimeter (nanoFOD) (DEVICE).
Who is sponsoring clinical trial NCT02040155?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02040155's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia